8 Inhibitors in congenital haemophilia

Addiego, 1993, Frequency of inhibitor development in haemophiliacs treated with low purity factor VIII, Lancet, 342, 462, 10.1016/0140-6736(93)91593-B Addiego, 1994, Increased frequency of inhibitors in African-American hemophilia A patients, Blood, 84, 239a Agrawal, 1981, Acute myocardial infarction in a young hemophiliac patient during therapy with factor IX concentrate and epsilon aminocaproic acid, Journal of Pediatrics, 98, 931, 10.1016/S0022-3476(81)80592-6 Antonarakis, 1995, Factor VIII gene inversions in severe hemophilia A: results of an international consortium study, Blood, 86, 2206, 10.1182/blood.V86.6.2206.bloodjournal8662206 Aznar, 1983, Suppression of inhibitors in haemophilia with corticoids and factor VIII, Thrombosis and Haemostasis, 49, 241 Berntorp, 1994, Immune tolerance and the immune modulation protocol. Blatt, 1977, Treatment of anti factor VIII antibodies, Thrombosis and Haemostasis, 38, 514, 10.1055/s-0038-1651858 Brachmann, 1986, Induced immune tolerance in factor VIII inhibitor patients, 150, 181 Bray, 1994, A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A, Blood, 83, 2428 Brettler, 1989, The use of porcine factor VIII concentrate in the treatment of patients with inhibitor antibodies to factor VIII:C. A multicenter US experience, Archives of Internal Medicine, 149, 1381, 10.1001/archinte.1989.00390060103022 Brettler, 1994, The price of immune tolerance program for factor VIII inhibitors in the New England area, are they worth it, Blood, 84, 201a Chavin, 1988, Acute myocardial during treatment with an activated prothrombin complex concentrate in a patient with FVIII deficiency and FVIII inhibitor, American Journal of Medicine, 85, 245, 10.1016/S0002-9343(88)80353-X Dahri, 1995, Synthetic sorbents for removal of factor VIII inhibitors from haemophilic A plasma, Journal of Chromatography B: Biomedical Applications, 664, 47, 10.1016/0378-4347(94)00350-E Ehrneforth, 1992, Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs, Lancet, 339, 594, 10.1016/0140-6736(92)90874-3 Ewing, 1988, Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors, Journal of the American Medical Association, 259, 65, 10.1001/jama.1988.03720010043038 Gordon, 1994, Continuous infusion of monoclonal antibody purified factor VIII: rational approach to serious hemorrhage in patients with allo/autoantibodies to factor VIII, American Journal of Hematology, 45, 142, 10.1002/ajh.2830450209 Gringeri, 1991, Adverse effects of treatment with porcine factor VIII, Thrombosis and Haemostasis, 65, 245, 10.1055/s-0038-1647658 Gringeri, 1991, Failure of recombinant activated factor VII during surgery in a hemophiliac with high titer factor VIII antibodies, Hemostasis, 221, 1 Hay, 1990, Induction of immune tolerance in patients with hemophilia A and inhibitors treated with porcine VIII: C by home therapy, Blood, 76, 882, 10.1182/blood.V76.5.882.882 Hedner, 1983, Use of human factor VIIa in the treatment of two hemophilia A patients with high titer inhibitors, Journal of Clinical Investigation, 71, 1836, 10.1172/JCI110939 Hedner, 1988, Successful use of recombinant factor VIIa in a patient with severe hemophilia A during synovectomy, Lancet, ii, 1193, 10.1016/S0140-6736(88)90259-0 Hoffman, 1994, Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high dose factor VIIa in hemophilia, Blood, 83, 38, 10.1182/blood.V83.1.38.38 Ingerslev, 1991, Control of haemostasis with recombinant factor VIIa in a patient with inhibitor to factor VIII, Lancet, 338, 831, 10.1016/0140-6736(91)90729-9 Kasper, 1975, A more uniform measurement of factor VIII inhibitors, Thrombosis et Diathesis Haemorrhagica, 34, 869 Katz, 1996, Prevalence of factor IX inhibitors among patients with hemophilia B: results of a large scale North American survey, Haemophilia, 10.1111/j.1365-2516.1996.tb00006.x Kernoff, 1984, Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII, Blood, 63, 31, 10.1182/blood.V63.1.31.31 Lozier, 1993, Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors, 30, 10 Lubin, 1994, Elimination of a major inhibitor epitope in factor VIII, Journal of Biological Chemistry, 269, 1, 10.1016/S0021-9258(17)37014-X Lusher, 1987, Factor VIII inhibitors: etiology, characterization, natural history and management, Annals of the New York Academy of Sciences, 509, 89, 10.1111/j.1749-6632.1987.tb30987.x Lusher, 1980, Efficacy of prothrombin complex concentrates in hemophiliacs with antibodies to factor VIII, New England Journal of Medicine, 303, 421, 10.1056/NEJM198008213030803 Lusher, 1983, Autoplex vs. proplex: A double controlled double blind study of effectiveness in acute hemarthrosis in hemophiliacs with inhibitors to factor VIII, Blood, 62, 1135, 10.1182/blood.V62.5.1135.1135 Lusher, 1990, Viral safety and inhibitor development associated with factor VIII ultra-purified from plasma in hemophiliacs previously unexposed to factor VIII:C concentrates, 27, 1 Lusher, 1993, Recombinant factor VIII for the treatment of previously untreated patients with hemophilia, New England Journal of Medicine, 328, 453, 10.1056/NEJM199302183280701 Macik, 1989, Use of recombinant activated factor VII for treatment of retropharyngeal hemorrhage in a hemophilic patient with high titer inhibitor, American Journal of Hematology, 32, 232, 10.1002/ajh.2830320315 McMillan, 1988, The natural history of factor VIII inhibitors in patients with hemophilia A: a national cooperative study, New England Journal of Medicine, 71, 344 Mariani, 1994, Immune tolerance in hemophilia—Principal results from an international registry, Thrombosis and Haemostasis, 72, 155, 10.1055/s-0038-1648828 Millar, 1990, The molecular genetic basis of hemophilia A: characterization of six partial deletions in the factor VIII gene, Human Genetics, 86, 219, 10.1007/BF00197709 Nilsson, 1981, A procedure for removing high titer antibodies by extracorporeal protein A sepharose adsorption in hemophilia, Blood, 58, 38, 10.1182/blood.V58.1.38.38 Nilsson, 1986, Induction of split tolerance and clinical cure in high responding hemophiliacs with factor IX antibodies, 83, 9169 Nilsson, 1988, Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide and factor VIII, New England Journal of Medicine, 328, 947, 10.1056/NEJM198804143181503 Peerlinck, 1993, A higher than expected incidence of factor VIII inhibitors in multitransfused hemophilia A patients treated with intermediate purity pasteurized factor VIII concentrate, Thrombosis and Haemostasis, 69, 115, 10.1055/s-0038-1651565 Reisner, 1993, Immunogenetics of human immune response to factor VIII Scandella, 1989, The localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization, Blood, 74, 1618, 10.1182/blood.V74.5.1618.1618 Sjamsoedin, 1981, The effect of activated prothrombin complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double blind clinical trial, New England Journal of Medicine, 305, 717, 10.1056/NEJM198109243051301 van Leeuwen, 1986, Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose, British Journal of Haematology, 64, 291, 10.1111/j.1365-2141.1986.tb04122.x Wansley, 1985, Induction of tolerance to factor VIII in hemophilia A patients with inhibitors using low doses of human factor VIII (abstract), Thrombosis and Haemostasis, 54, 227